Omni-stat Medical Inc launches hemostat comprised of their proprietary chitosan technology and proven on the battlefield to the US hospital market

Omni-stat Medical Inc was recently established in 2018 to provide a solution to bleeding control in a hospital setting.  OMNI-STAT® is made of a proprietary composition which contains chitosan in the form of macroscopic high surface area granular flakes.  This technology was first cleared by the FDA in 2006 and was sold to the US Military under the brand name CELOX™.   Already in use by the special forces, in 2014, CELOX was added to the US Department of Defense’s Committee on Tactical Combat Casualty Care (CoTCCC) for military wide use.  Now for the first time, a dedicated team has been established to introduce this product to the US hospital market. 

“We recognize the unique challenges healthcare professionals face when presented with bleeding wounds that vary broadly across the spectrum of medicine.  We want to offer the same unique proprietary technology behind CELOX, beyond the military, and make it available to US hospitals.  OMNI-STAT® offers a variety of preparations and can be used as a  fast and effective solution to achieve rapid hemostasis for minor, moderate and severe bleeding, which may allow for shorter patient length of stay, and better management of staffing resources by reducing blood loss and the associated risks,” said Gina Milner, director of US commercial operations.

“Our goal is to meet the needs of patients, and we are committed to offering the best healthcare solutions at low overall cost.  Together, we can help reduce blood loss and save lives, all within minutes.”